Ian Lee1, Steven Kalkanis, Constantinos G Hadjipanayis. 1. *Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan; ‡Department of Neurosurgery, Mt. Sinai Beth Israel Hospital, New York City, New York.
Abstract
BACKGROUND: The value of maximal safe cytoreductive surgery in recurrent high-grade gliomas (HGGs) is gaining wider acceptance. However, patients may harbor recurrent tumors that may be difficult to access with open surgery. Laser interstitial thermal therapy (LITT) is emerging as a technique for treating a variety of brain pathologies, including primary and metastatic tumors, radiation necrosis, and epilepsy. OBJECTIVE: To review the role of LITT in the treatment of recurrent HGGs, for which current treatments have limited efficacy, and to discuss the possible role of LITT in the disruption of the blood-brain barrier to increase delivery of chemotherapy locoregionally. METHODS: A MEDLINE search was performed to identify 17 articles potentially appropriate for review. Of these 17, 6 reported currently commercially available systems and as well as magnetic resonance thermometry to monitor the ablation and, thus, were thought to be most appropriate for this review. These studies were then reviewed for complications associated with LITT. Ablation volume, tumor coverage, and treatment times were also reviewed. RESULTS: Sixty-four lesions in 63 patients with recurrent HGGs were treated with LITT. Frontal (n = 34), temporal (n = 14), and parietal (n = 16) were the most common locations. Permanent neurological deficits were seen in 7 patients (12%), vascular injuries occurred in 2 patients (3%), and wound infection was observed in 1 patient (2%). Ablation coverage of the lesions ranged from 78% to 100%. CONCLUSION: Although experience using LITT for recurrent HGGs is growing, current evidence is insufficient to offer a recommendation about its role in the treatment paradigm for recurrent HGGs. ABBREVIATIONS: BBB, blood-brain barrierFDA, US Food and Drug AdministrationGBM, glioblastoma multiformeHGG, high-grade gliomaLITT, laser interstitial thermal therapy.
BACKGROUND: The value of maximal safe cytoreductive surgery in recurrent high-grade gliomas (HGGs) is gaining wider acceptance. However, patients may harbor recurrent tumors that may be difficult to access with open surgery. Laser interstitial thermal therapy (LITT) is emerging as a technique for treating a variety of brain pathologies, including primary and metastatic tumors, radiation necrosis, and epilepsy. OBJECTIVE: To review the role of LITT in the treatment of recurrent HGGs, for which current treatments have limited efficacy, and to discuss the possible role of LITT in the disruption of the blood-brain barrier to increase delivery of chemotherapy locoregionally. METHODS: A MEDLINE search was performed to identify 17 articles potentially appropriate for review. Of these 17, 6 reported currently commercially available systems and as well as magnetic resonance thermometry to monitor the ablation and, thus, were thought to be most appropriate for this review. These studies were then reviewed for complications associated with LITT. Ablation volume, tumor coverage, and treatment times were also reviewed. RESULTS: Sixty-four lesions in 63 patients with recurrent HGGs were treated with LITT. Frontal (n = 34), temporal (n = 14), and parietal (n = 16) were the most common locations. Permanent neurological deficits were seen in 7 patients (12%), vascular injuries occurred in 2 patients (3%), and wound infection was observed in 1 patient (2%). Ablation coverage of the lesions ranged from 78% to 100%. CONCLUSION: Although experience using LITT for recurrent HGGs is growing, current evidence is insufficient to offer a recommendation about its role in the treatment paradigm for recurrent HGGs. ABBREVIATIONS: BBB, blood-brain barrierFDA, US Food and Drug AdministrationGBM, glioblastoma multiformeHGG, high-grade gliomaLITT, laser interstitial thermal therapy.
Authors: Jaclyn J Renfrow; Roy E Strowd; Adrian W Laxton; Stephen B Tatter; Carol P Geer; Glenn J Lesser Journal: Curr Treat Options Oncol Date: 2017-08
Authors: Tavarekere N Nagaraja; Seamus Bartlett; Katelynn G Farmer; Glauber Cabral; Robert A Knight; O Grahm Valadie; Stephen L Brown; James R Ewing; Ian Y Lee Journal: Acta Neurochir (Wien) Date: 2021-09-23 Impact factor: 2.216
Authors: Georgios P Skandalakis; Daniel R Rivera; Caroline D Rizea; Alexandros Bouras; Joe Gerald Jesu Raj; Dominique Bozec; Constantinos G Hadjipanayis Journal: Int J Hyperthermia Date: 2020-07 Impact factor: 3.914
Authors: Elsa V Arocho-Quinones; Sean M Lew; Michael H Handler; Zulma Tovar-Spinoza; Matthew Smyth; Robert Bollo; David Donahue; M Scott Perry; Michael L Levy; David Gonda; Francesco T Mangano; Phillip B Storm; Angela V Price; Daniel E Couture; Chima Oluigbo; Ann-Christine Duhaime; Gene H Barnett; Carrie R Muh; Michael D Sather; Aria Fallah; Anthony C Wang; Sanjiv Bhatia; Kadam Patel; Sergey Tarima; Sarah Graber; Sean Huckins; Daniel M Hafez; Kavelin Rumalla; Laurie Bailey; Sabrina Shandley; Ashton Roach; Erin Alexander; Wendy Jenkins; Deki Tsering; George Price; Antonio Meola; Wendi Evanoff; Eric M Thompson; Nicholas Brandmeir Journal: J Neurosurg Pediatr Date: 2020-03-27 Impact factor: 2.375